Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma

Han, Xiao; Ruan, Jing; Zhou, Daobin; Xu, Dongsheng; Pei, Qiang; Ouyang, Mingqi; Zuo, Mengxuan

doi:10.18632/oncotarget.17830

Cited by 12 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies indicated circulating CD16 + monocytes predicted prognosis in solid tumors 7 . Our team also found for the first time that the lower CD16− monocytes/CD16 + monocytes ratio was related to worse survival in DLBCL without known mechanisms 5 . In this study, we explored the clinical value of monocyte subsets in T-NHL and the potential mechanisms.…”

Section: -/Cd16 + Monocytes Predict the Prognosis Of T Cell Lympsupporting

confidence: 52%

“…Tumor microenvironment especially the tumor-associated macrophage (TAM) has been recognized as a promising predictive marker in lymphoma 4 and peripheral blood monocytes are considered the major sources of TAMs. In a recent study we found for the first time that the lower CD16− monocytes/CD16− monocytes ratio seemed to indicate the worse prognosis of diffuse large B cell lymphoma (DLBCL) 5 . Therefore, we prostitute CD16−/CD16 + monocytes may reflect tumor microenvironment and may also be used to predict the survival of T-NHL.…”

mentioning

confidence: 95%

See 1 more Smart Citation

Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16−/CD16 + monocyte ratio

Ruan

Zhou

Han

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

t cell non-Hodgkin lymphoma (t-nHL) is highly invasive and heterogeneous without accurate prognosis prediction. We proposed peripheral CD16−/CD16 + monocytes the additional indicators for t-nHL prognosis. We prospectively recruited 31 T-NHL patients without previous treatment. The CD16−/ CD16 + monocyte ratio before chemotherapy was calculated and regular follow up was performed to calculate prognostic prediction value. tumor associated macrophages (tAM) in tumor tissue were counted and transcriptome sequencing of CD16− and CD16 + monocytes was applied to explore potential mechanisms. We found that t-nHL patients had higher ratio of total monocytes especially the CD16 + monocytes along with a decreased ratio of CD16−/CD16 + monocytes, compared to the health control. The 1-year overall survival rate was 0.492 and 0.755 for CD16− monocyte/CD16 + monocyte ratio of <11 and ≥11(p < 0.05), respectively. The peripheral CD16−/CD16 + monocyte ratio was significantly relevant with the pathological CD68/CD206 macrophage ratio. The differently expressed genes in CD16− and CD16 + monocytes from t-nHL patients were mainly involved in signaling molecules related to tumor microenvironment. Pro-tumor genes were identified in monocyte subsets especially in CD16 + monocytes. In conclusion, the ratio of peripheral CD16−/CD16 + monocyte helps to stratify the prognosis of T-NHL. The relatively increased CD16 + monocytes may contribute to the pro-tumor microenvironment of t-nHL.

show abstract

Section: -/Cd16 + Monocytes Predict the Prognosis Of T Cell Lympsupporting

confidence: 52%

mentioning

confidence: 95%

Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16−/CD16 + monocyte ratio

Ruan

Zhou

Han

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Shi et al reported that diffuse large B cell lymphoma (DLBCL) patients with high CD8‐positive T cells and tumoural PD‐L1 expression showed better survival, irrespective of rituximab treatment . However, other researchers reported that an increase in CD8‐positive or TIA1‐positive cytotoxic T cells was associated with poor prognosis in DLBCL patients . In the current study, CD8‐positive T cells showed no definitive role in the better prognosis of ATLL patients.…”

Section: Discussionmentioning

confidence: 99%

Cytological tumour cell characteristics and reactive small lymphocytes influence patient prognosis in acute and lymphoma type adult T‐cell leukaemia/lymphoma

et al. 2019

View full text Add to dashboard Cite

Objective: Acute and lymphoma type adult T-cell leukaemia/lymphoma (ATLL) patients show an aggressive clinical course. While some clinical signs indicate good prognosis, definitive cytohistological prognostic factors have yet to be described. Methods:We classified 65 ATLL patients into three groups by tumour cell size and nuclear pleomorphism on fine-needle aspiration and tumour touch smear samples.Semi-quantitative analysis of background small lymphocytes, reactive CD20-positive B cells and CD8-positive T cells was performed.Results: Thirty-one patients had pleomorphic lymphoma with predominantly medium-sized cells and coarse granular nuclei. Another 24 patients showed pleomorphic large cell lymphoma with stippled chromatin. The remaining 10 demonstrated monomorphic large lymphoma cells with fine granular chromatin. Patients with pleomorphic lymphoma with medium-sized cells showed significantly higher serum lactate dehydrogenase and lower CD30 and C-MYC expression in lymphoma cells than the other two groups (P = .0216, P < 0.01, respectively). Patients with pleomorphic medium-sized ATLL had few usual small lymphocytes observed on routine morphological examination and showed less concurrent detection of CD20-positive B cells and CD8-positive T cells, both of which were lower than in the other two groups (P = .006, P = .019, respectively). Furthermore, ATLL patients with predominantly medium-sized lymphocytes exhibited a worse prognosis than patients with pleomorphic large cells (P = .0197). Background small lymphocytes and concurrent detection of CD20-positive B cells and CD8-positive T cells may thus be good prognostic factors (P = .011, P = .021, respectively). Conclusions:Morphological features, size of neoplastic cells and background nonneoplastic lymphocyte (B cells and CD8-positive T cells) volume appear to influence the prognosis of patients with aggressive-type ATLL. K E Y W O R D Sadult T-cell leukaemia/lymphoma, cytology, prognosis, tumour-infiltrating lymphocytes | 403 KOBATA eT Al.

show abstract

“…In AML, defective NK cells at diagnosis are associated with increased risk of relapse and transcriptional analysis shows differential expression of TGF-β signaling pathways between highly functional NK cells and dysfunctional NK cells from patients with leukemia [ 3 ]. Decreased number and function of NK cells in the TME of lymphoma predicts a poor prognosis [ 203 ]. Similar to other solid tumors, TGF-β is expressed at high levels by both lymphoma cells and regulatory T cells within the lymphoma tumor microenvironment which is likely one of the immune escape mechanisms employed by lymphomas [ 204 , 205 ].…”

Section: Barriers To Nk Cell Success and Solutionsmentioning

confidence: 99%

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future

et al. 2021

View full text Add to dashboard Cite

The adoptive transfer of natural killer (NK) cells is an emerging therapy in the field of immuno-oncology. In the last 3 decades, NK cells have been utilized to harness the anti-tumor immune response in a wide range of malignancies, most notably with early evidence of efficacy in hematologic malignancies. NK cells are dysfunctional in patients with hematologic malignancies, and their number and function are further impaired by chemotherapy, radiation, and immunosuppressants used in initial therapy and hematopoietic stem cell transplantation. Restoring this innate immune deficit may lead to improved therapeutic outcomes. NK cell adoptive transfer has proven to be a safe in these settings, even in the setting of HLA mismatch, and a deeper understanding of NK cell biology and optimized expansion techniques have improved scalability and therapeutic efficacy. Here, we review the use of NK cell therapy in hematologic malignancies and discuss strategies to further improve the efficacy of NK cells against these diseases.

show abstract

Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma

Cited by 12 publications

References 47 publications

Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16−/CD16 + monocyte ratio

Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16−/CD16 + monocyte ratio

Cytological tumour cell characteristics and reactive small lymphocytes influence patient prognosis in acute and lymphoma type adult T‐cell leukaemia/lymphoma

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future

Contact Info

Product

Resources

About